Despite IV Vancomycin`s Stronghold on the MRSA Antibiotic Hospital Market, Surveyed ID Specialists Report Shifting Away from IV Vancomycin to Branded Agents, Including Pfizer`s Zyvox and Cubist/Novartis`s Cubicin